8RP.F CELON PHARMA S.A. ZY-10

Healthcare Pharmaceuticals Frankfurt Exchange
3.53 EUR
Close of Nov 11, 2026
3.53 5.77
Market cap
EUR 190M
P/E
7.4x
P/B
1.68x
ROE
53.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 8RP.F undervalued?

Graham number
Price3.53
Graham value4.76
Discount25.9%

8RP.F trades 25.9% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CELON PHARMA S.A. ZY-10 fundamental analysis

No fundamental analysis for CELON PHARMA S.A. ZY-10 yet.

CELON PHARMA S.A. ZY-10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CELON PHARMA S.A. ZY-10

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.

Full company profile